Unknown

Dataset Information

0

Brief clinical evaluation of six high-throughput SARS-CoV-2 IgG antibody assays.


ABSTRACT: Serological SARS-CoV-2 assays are urgently needed for diagnosis, contact tracing and for epidemiological studies. So far, there is limited data on how recently commercially available, high-throughput immunoassays, using different recombinant SARS-CoV-2 antigens, perform with clinical samples. Focusing on IgG and total antibodies, we demonstrate the performance of four automated immunoassays (Abbott Architect™ i2000 (N protein-based)), Roche cobas™ e 411 analyzer (N protein-based, not differentiating between IgA, IgM or IgG antibodies), LIAISON®XL platform (S1 and S2 protein-based), VIRCLIA® automation system (S1 and N protein-based) in comparison to two ELISA assays (Euroimmun SARS-CoV-2 IgG (S1 protein-based) and Virotech SARS-CoV-2 IgG ELISA (N protein-based)) and an in-house developed plaque reduction neutralization test (PRNT). We tested follow up serum/plasma samples of individuals PCR-diagnosed with COVID-19. When calculating the overall sensitivity, in a time frame of 49 days after first PCR-positivity, the PRNT as gold standard, showed the highest sensitivity with 93.3% followed by the dual-target assay for the VIRCLIA® automation system with 89%. The overall sensitivity in the group of N protein-based assays ranged from 66.7 to 77.8% and in the S protein-based-assays from 71.1 to 75.6%. Five follow-up samples of three individuals were only detected in either an S and/or N protein-based assay, indicating an individual different immune response to SARS-CoV-2 and the influence of the used assay in the detection of IgG antibodies. This should be further analysed. The specificity of the examined assays was ? 97%. However, because of the low or unknown prevalence of SARS-CoV-2, the examined assays in this study are currently primarily eligible for epidemiological investigations, as they have limited information in individual testing.

SUBMITTER: Kohmer N 

PROVIDER: S-EPMC7263247 | biostudies-literature | 2020 Jun

REPOSITORIES: biostudies-literature

altmetric image

Publications

Brief clinical evaluation of six high-throughput SARS-CoV-2 IgG antibody assays.

Kohmer Niko N   Westhaus Sandra S   Rühl Cornelia C   Ciesek Sandra S   Rabenau Holger F HF  

Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 20200601


Serological SARS-CoV-2 assays are urgently needed for diagnosis, contact tracing and for epidemiological studies. So far, there is limited data on how recently commercially available, high-throughput immunoassays, using different recombinant SARS-CoV-2 antigens, perform with clinical samples. Focusing on IgG and total antibodies, we demonstrate the performance of four automated immunoassays (Abbott Architect™ i2000 (N protein-based)), Roche cobas™ e 411 analyzer (N protein-based, not differentia  ...[more]

Similar Datasets

| S-EPMC7444492 | biostudies-literature
| S-EPMC8093006 | biostudies-literature
| S-EPMC7916820 | biostudies-literature
| S-EPMC8888213 | biostudies-literature
| S-EPMC8178338 | biostudies-literature
| S-EPMC7605757 | biostudies-literature
| S-EPMC7524664 | biostudies-literature
| S-EPMC8801209 | biostudies-literature
| S-EPMC8289701 | biostudies-literature
| S-EPMC9044730 | biostudies-literature